Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
PL75, your reply to Mark wasn't missed here. Concise, effective and deserved.
Mark - riddle me this: if you’ve been waiting since “last summer”, when the price was below £2, and it’s now April, and the price is £2.40, how are you a “lamb to the slaughter”? How have you managed to be losing money here?!
Poor attempt!
Smashing essay gkb. We are where we are. You've sold half, you still sound miserable, why not sell the other half? You'll be in profit, you can be pleased with yourself and put the cash somewhere else with better potential - got any suggestions?
Btw, the Deepverge test is owned by them, the contract was to supply affimers if they want some, so there's nothing to report at all and never will be, so head over and moan on their board.
Good point gkb I reckon we should bin the whole thing and stick to the INNOVA tests
Heartbreaking Markb. Which part of struggle to meet demand are you having difficulty with?
Thanks for answering my question Mark. Both.
I tried but people like Mark drive me to it.
Mark your a TWAT.
One significant advantage that NCYT has is access to samples. However, it will be interesting to see what their 3rd party clinical validation programme looks like!
Are people really that thick? If disingenuous, it's just embarrassing.
MarkBGoldRush
Our test, based on the 3rd party clinical validation, is the best performing LFT globally, so if it is not good enough for home use then nothing is good enough for home use.
InfinisandBeyond,
AVCT strategy, as they announced yesterday, was to focus on OEM and Licensing deals. Agreeing such a deal with NCYT fits the bill exactly. It would not be a competing test if the test was powered by Affimers - it would be direct profit to AVCT.
Where did he say not targeting UK sales or are you making $hit up. I heard him say along the lines of at the minute government is giving them away for free (To me means not much point selling them in boots if the Government is giving them away) Said the route to market was through government in the UK hence the discussions with DHSC and PHE.
Having said that as I have said before more money outside UK.
LOL. Of course there are no UK sales. The gov are going to buy up ÂŁ8 billion worth of them and give them away.
Pathetic attempt.
Wiggly - why on earth would Avacta give access to affimers for NYCT to generate a competing test? Doesn't make any sense. On the other hand if NYCT wanted to use some f their cash pile to crank up kit and machinery to be a manufacturing partner for Avacta then why not...
License Agreement with Astrea Bioseparations for the use of the Affimer platform for affinity purification applications..
Very little discussion about this...and in itself could be an industry game changer....
AVACTA had ÂŁ47.9m cash at the end of the year, having incurred losses of ÂŁ18.9m.
Upcoming milestones include self-declaration of the CE mark of its Covid test for professional use and commercial launch in early May, and the first data on the effectiveness of its targeted chemotherapy platform pre|CISION in humans by the end of the year.
AVACTA is about affimers..New tech which is already being picked up in different areas other than LFTs...
Don't be blinkered by pure test play...affimers are a new and far more accurate industry disrupter at the very very early stages of its life span...
The unnamed NCYT LFT partner. Adding 2+2 and coming up with X however, hear me out;
- AVCT are working with almost all UK manufacturer's - BBI, Abington, ODX, Mol/GAD...thus it is not far fetched to consider that they would also partner with NCYT
- NCYT and partner are working on an AN sample method LFT - match with GAD/AVCT
- Matches all known variants
- So far, the GAD/AVCT LFT delivers unbeatable S&S - not sure it would make sense for NCYT to partner with anyone else?
- 5-30m UK capacity - does this include potential through partners such as NCYT?
- results in approx. 15m - well that sits nicely bang centre of the read time 10-20 minutes for the GAD/AVCT test
As AVCT are directly pushing OEM and licencing deals, and with S&S at 100/99 (CT < 27) I would find it strange if they had not engaged NCYT to discuss working together / increasing capacity.
Any thoughts on why it would be unlikely for AVCT/GAD to be in discussions with NCYT?
If NCYT are partnering with someone, their s/s will very unlikely be market leading especially without the amount of time tweaking required to refine the s/s. Good luck to them whatever they make, I'm sure it'll sell.
Although what a great plot twist if AffiRx's first customer is NCYT and they're using our magic beans for their saliva test :-) We will harpoon a few big fish that want a slice of the LFT pie I am sure, what better way than to utilise the most specific of technologies (oh and 100% sensitive to infectious level viral loads, too!).
No offence meant. Always had an interest in AVCT and there should be more than ample opportunity on the LFT front for both concerns.
Just when you think the childish, utterly stupid and pointless cross board battles have finished... (where’s my covfefe today?)
Seriously, good luck with ncyt, hope it works out. Another product, among the hundreds that are out there won’t make a difference as demand for a 98/99 LFD hugely outstrips supply.
Don't you mean you "hope" it shocked us? And please don't insult our intelligence by suggesting that we are blinkered to events elsewhere in the market.
Naewise,
Yes it's a very good RNS and I'm delighted for them, however it makes zero difference to Avactas test and/or commercial rollout
Read it couldn't find the S & S figures can you point me to them or shall I ask on the NCYT board?
Thanks
Have you seen NCYTs RNS this morning? Very comprehensive and now streets ahead on the LFT front amongst many others. Suggest you have a read. It might shock you.
Novacyt know PCR testing surge has passed and are looking for new ways to make money now..... but they're a long way behind Avacta when it comes to LFTs.
I'd be shocked if they produce anything close to our test within that time frame.
Maybe we will use our affirmers.
Regardless, there's enough demand to have many companies producing millions per month